Clinical Trial Update: A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase I study is evaluating [225Ac]-AZD2284 in metastatic castration-resistant prostate cancer, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• [225Ac]-AZD2284 (AZD2284)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Status: RECRUITING